"The US Food and Drug Administration (FDA) has approved an expanded indication for onabotulinum toxin A (Botox, Actavis) for the treatment of adults with upper limb spasticity, according to a company news release.
The expanded i"...
- Advise patients and caregivers of the need to maintain dietary restriction of tyrosine and phenylalanine when taking ORFADIN to treat hereditary tyrosinemia type 1 [see WARNINGS AND PRECAUTIONS].
- Advise patients and caregivers to report promptly unexplained eye symptoms, rash, jaundice, or excessive bleeding [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
Last reviewed on RxList: 7/15/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Orfadin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.